Nichi-Iko Pharmaceutical and Nipro said on September 2 that their generic versions of the cancer drug Halaven (eribulin) have won an additional indication for soft tissue sarcoma.The generics, Eribulin Mesilate IV Injection “Nichi-Iko” and “Nipro,” were previously approved for inoperable…
To read the full story
BUSINESS
- Ex-Takeda CEO Weber Joins Rakuten Medical as Vice Chairman
September 10, 2026
- 3 Chugai Researchers Win Lasker Award for Hemlibra Discovery
September 10, 2026
- Elix, Axcelead DDP Forge Pact on Novel Protein Degraders
September 10, 2026
- CMIC Scraps Application Forms, Brings AI Avatars into New Grad Hiring
September 10, 2026
- Teijin, Shinshu University Link Arms on CAR-T Manufacturing
September 10, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





